Verastem Oncology to Present at Upcoming Investor Conferences

5/1/25 7:30:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $VSTM alert in real time by email

Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate and present at the following investor conferences in May:

H.C. Wainwright 3^rd Annual BioConnect Investor Conference: Fireside chat on Tuesday, May 20 at 12:00 pm ET
2025 RBC Capital Markets Global Healthcare Conference: Fireside chat on Tuesday, May 20 at 3:35 pm ET
Alliance Global Partners/A.G.P.'s Annual Healthcare Company Showcase: Virtual fireside chat on Wednesday, May 21 at 10:20 am ET

A live webcast of the fireside chats can be accessed under events on Verastem Oncology's website at www.verastem.com. A replay of the webcasts will be archived on the website for approximately 90 days following the presentation.

About Verastem Oncology

Verastem Oncology (NASDAQ:VSTM) is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Our pipeline is focused on novel small-molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition. For more information, please visit www.verastem.com and follow us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250501095515/en/

For Investor and Media Inquiries:

Julissa Viana

Vice President, Corporate Communications,

Investor Relations & Patient Advocacy

[email protected] or

[email protected]

Get the next $VSTM alert in real time by email

Recent Analyst Ratings for

$VSTM

Date	Price Target	Rating	Analyst
4/10/2025	$15.00	Buy	Jefferies
3/24/2025	$7.00 → $10.00	Buy	H.C. Wainwright
12/31/2024	$13.00 → $20.00	Buy	BTIG Research
9/30/2024	$13.00	Buy	Guggenheim
11/21/2023	$27.00	Buy	BTIG Research
9/27/2023	$21.00	Buy	B. Riley Securities
6/15/2023	$24.00 → $36.00	Neutral → Buy	Mizuho
9/7/2022	$6.00	Buy	Alliance Global Partners

More analyst ratings

Verastem Oncology to Present at Upcoming Investor Conferences

Chat with this insight

Recent Analyst Ratings for
$VSTM

$VSTM
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

President and CEO Paterson Dan sold $1,893 worth of shares (335 units at $5.65), decreasing direct ownership by 0.07% to 461,647 units (SEC Form 4)

Director Gagnon Robert E. sold $1,605 worth of shares (284 units at $5.65), decreasing direct ownership by 0.67% to 42,242 units (SEC Form 4)

Director Stuglik Brian M sold $3,356 worth of shares (594 units at $5.65), decreasing direct ownership by 0.58% to 102,326 units (SEC Form 4)

$VSTM
Press Releases

Fastest customizable press release news feed in the world

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor

Verastem Oncology to Present at the Jefferies Global Healthcare Conference

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma

$VSTM
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Rowinsky Eric K bought $7,680 worth of shares (2,000 units at $3.84) (SEC Form 4)

$VSTM
SEC Filings

Verastem Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

Verastem Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

Verastem Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

Verastem Oncology to Present at Upcoming Investor Conferences

Chat with this insight

Recent Analyst Ratings for $VSTM

$VSTM Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

President and CEO Paterson Dan sold $1,893 worth of shares (335 units at $5.65), decreasing direct ownership by 0.07% to 461,647 units (SEC Form 4)

Director Gagnon Robert E. sold $1,605 worth of shares (284 units at $5.65), decreasing direct ownership by 0.67% to 42,242 units (SEC Form 4)

Director Stuglik Brian M sold $3,356 worth of shares (594 units at $5.65), decreasing direct ownership by 0.58% to 102,326 units (SEC Form 4)

$VSTM Press Releases

Fastest customizable press release news feed in the world

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor

Verastem Oncology to Present at the Jefferies Global Healthcare Conference

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma

$VSTM Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Rowinsky Eric K bought $7,680 worth of shares (2,000 units at $3.84) (SEC Form 4)

$VSTM SEC Filings

Verastem Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

Verastem Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

Verastem Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

Recent Analyst Ratings for
$VSTM

$VSTM
Insider Trading

$VSTM
Press Releases

$VSTM
Insider Purchases

$VSTM
SEC Filings